Dr. M. Meyer and others in our lab, working with collaborators, completed a study published in Science TM. We compared the efficacy of 5 Ebola vaccines in NHPs and analyzed 139 immune parameters;Fc-mediated effects and GP specificity are central to protection. #VACCINE#immunity
NIAID has awarded me and Mariano Garcia-Blanco a $13.3M program P01 grant Molecular Mechanisms of the Dysregulated Immune Response to Ebola Virus. The project also involves Ricardo Rajsbaum, Andrew Routh, Thomas Geisbert, Ivan Marazzi and Stuart Sealfon and Matt Weirauch.
Marburg VLPs expressed by MVA vaccinia virus: authentic conformation of the Marburg envelope protein and limited replication. Working with our partners at GeoVax, Delphine Malherbe in our lab demonstrated excellent protection - NPJ Vaccines
https://t.co/yaCxu6CqRo
#vaccine#ebola
In a new paper in Cell Reports, our lab, working with the lab of Raul Andino, UCSF, demonstrated ADAR editing of Ebola genome during passages in bat but not in human cells.
https://t.co/1QXGlkvq0I
#Ebola#antibody#bats#virus#utmb#pathology
https://t.co/NDgahzNeYp
Some antibodies in the survivor of Marburg viurus infection bind to the envelope protein of the virus and recruit immune cells that kill infected cells, and also rearrange the protein to facilitate access for other antibodies which kill the virus.
Scientists in our lab found several candidate microRNAs in human and bat cells infected with Ebola virus. We found evidence contrary to the idea that these small RNA products function as microRNAs.
https://t.co/ZmwGkJ0q5O